Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
Reported Earlier, Innovent Receives FDA Fast Track Designation For IBI363, A PD-1/IL-2α Bispecific Antibody, As Monotherapy For Advanced Melanoma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.